Intravenous Cardioversion of Atrial Fibrillation (AF) With AZD1305
NCT ID: NCT00915356
Last Updated: 2012-02-01
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
228 participants
INTERVENTIONAL
2009-05-31
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cardiac Electrophysiological Study
NCT00616629
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
NCT04571385
Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation
NCT00255281
Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation.
NCT00035451
Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter
NCT00115791
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
AZD1305 iv infusion
AZD1305
Intravenous (iv) single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
2
Placebo iv infusion
Placebo
iv single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD1305
Intravenous (iv) single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
Placebo
iv single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Current episode of Atrial Fibrillation (ie irregular heart rhythm) lasting up to 3 months at randomisation
* Adequate anticoagulation according to international guidelines (ACC/AHA/ESC, 2006) or national guidelines
Exclusion Criteria
* QTcF interval \>440 ms
20 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AZD1305 Medical Science Director
Role: STUDY_DIRECTOR
AstraZeneca R&D, Mölndal, Sweden
Aladár Rónaszéki
Role: PRINCIPAL_INVESTIGATOR
Péterfy HospitalDepartment of Cardiology1076 Budapest, Péterfi Sándor str. 8-20HUNGARY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Brno, CZ, Czechia
Research Site
Prague, , Czechia
Research Site
Znojmo, , Czechia
Research Site
Aalborg, , Denmark
Research Site
Esbjerg, , Denmark
Research Site
Svendborg, , Denmark
Research Site
Budapest, , Hungary
Research Site
Cegléd, , Hungary
Research Site
Debrecen, , Hungary
Research Site
Kecskemét, , Hungary
Research Site
Székesfehérvár, , Hungary
Research Site
Breda, , Netherlands
Research Site
Deventer, , Netherlands
Research Site
Leeuwarden, , Netherlands
Research Site
Sneek, , Netherlands
Research Site
Hamar, , Norway
Research Site
Oslo, , Norway
Research Site
Rud, , Norway
Research Site
Tromsø, , Norway
Research Site
Bytom, , Poland
Research Site
Lubin, , Poland
Research Site
Płock, , Poland
Research Site
Ruda Śląska, , Poland
Research Site
Torun, , Poland
Research Site
Warsaw, , Poland
Research Site
Martin, , Slovakia
Research Site
Nitra, , Slovakia
Research Site
Ružomberok, , Slovakia
Research Site
Linköping, , Sweden
Research Site
Örebro, , Sweden
Research Site
Stockholm, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ronaszeki A, Alings M, Egstrup K, Gaciong Z, Hranai M, Kiraly C, Sereg M, Figatowski W, Bondarov P, Johansson S, Frison L, Edvardsson N, Berggren A. Pharmacological cardioversion of atrial fibrillation--a double-blind, randomized, placebo-controlled, multicentre, dose-escalation study of AZD1305 given intravenously. Europace. 2011 Aug;13(8):1148-56. doi: 10.1093/europace/eur120. Epub 2011 May 11.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-009862-15 (EudraCT No)
Identifier Type: -
Identifier Source: secondary_id
D3191C00009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.